This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2001;285:1283.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A nitric oxide (NO)–releasing form of aspirin shows promise in animal studies as a way to prevent scarring and reclogging of blood vessels after angioplasty, according to a team of researchers from Italy and the United States (Proc Natl Acad Sci U S A. 2001;98:2860-2864).

Investigators from Italy's University of Naples and University of Salerno; the University of California, Los Angeles, School of Medicine; and the University of California, San Diego, School of Medicine discovered that even low dosages of NCX-4016, the NO–releasing aspirin derivative, were significantly more effective than aspirin alone in reducing postangioplasty restenosis in mice that are genetically prone to develop atherosclerosis when fed a high-cholesterol diet. The protective effect was even greater when the drug was given 1 week before angioplasty.

Furthermore, while the mice given aspirin showed "both a severe mucosal and ulcerogenic damage induced by the aspirin," the animals given . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?